Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
Eotaxin-3, as a marker for eosinophilic esophagitis and methods of assessing, mitigating, and monitoring eosinophilic esophagitis by altering eotaxin-3 and/or CCR3 function, are disclosed.
1. A diagnostic method for eosinophilic esophagitis, comprising:
providing a sample from a patient suspected of having eosinophilic esophagitis, wherein the sample comprises blood anticoagulated with heparin;
detecting, from the patient sample, an elevated level of eotaxin-3 protein, wherein the level of eotaxin- 3 protein in the patient sample is at least about 20 pg/mL or higher than the level of eotaxin-3 protein in a normal sample; and
diagnosing eosinophilic esophagitis in the patient based on the presence of the elevated level of eotaxin-3 protein in the patient sample.
2. A diagnostic method for eosinophilic esophagitis, comprising:
providing a sample from a patient suspected of having eosinophilic esophagitis, wherein the sample comprises blood anticoagulated with EDTA;
detecting, from the patient sample, an elevated level of eotaxin-3 protein, wherein the level of eotaxin-3 protein in the patient sample is at least about 8 pg/mL or higher than the level of eotaxin-3 protein in a normal sample; and
diagnosing eosinophilic esophagitis in the patient based on the presence of the elevated level of eotaxin-3 protein in the patient sample.
3. The diagnostic method of claim 1 or claim 2 , further comprising:
applying the patient sample to an anti-eotaxin-3 antibody and at least one reagent, wherein the at least one reagent, when combined with the anti-eotaxin-3 antibody, indicates the presence or absence of binding between eotaxin-3 and anti-eotaxin-3 antibody, and
determining the level of binding of the anti-eotaxin-3 antibody with eotaxin-3 present in the patient sample, wherein an elevated level of binding indicates an elevated level of eotaxin-3 protein.
4. The diagnostic method of claim 3 , further comprising:
reacting, in both the patient sample and normal sample, the at least one reagent with a chromogenic, fluorogenic, or luminescent substrate, wherein the presence of a stronger signal in the patient sample than that in the normal sample indicates binding of the anti-eotaxin-3 antibody to eotaxin-3 present in an elevated level in the patient sample.
5. The diagnostic method of claim 3 , wherein the at least one reagent comprises an enzyme selected from the group consisting of an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase, and a ligase.
6. The diagnostic method of claim 3 , wherein the anti-eotaxin-3 antibody is a purified antibody which binds to a murine or human eotaxin-3protein, and wherein the anti-eotaxin-3 antibody is selected from the group consisting of an intact monoclonal antibody, a polyclonal antibody, and an immunologically active antibody fragment.
7. The diagnostic method of claim 3 , wherein an ELISA device or a test strip is used to contain the anti-eotaxin-3 antibody and the reagent.